Expert Opinion on Pharmacotherapy

Article	Citations
Neoadjuvant or adjuvant chemotherapy in early breast cancer?	58
Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention	47
Pneumocystis jirovecii: a review with a focus on prevention and treatment	40
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis	39
Current pharmacological approaches to the treatment of tendinopathy	35
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction	29
Capsaicin 8% dermal patch in clinical practice: an expert opinion	28
An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection	27
Can NSAIDs and Acetaminophen Effectively Replace Opioid Treatment Options for Acute Pain?	25
Are 5-HT1 receptor agonists effective anti-migraine drugs?	24
New anti-seizure medication for elderly epilepsy patients - a critical narrative review	24
An update on direct antiviral agents for the treatment of hepatitis C	24
The limits and challenges of antiobesity pharmacotherapy	23
Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspective	22
Current and new pharmacotherapy options for non-alcoholic steatohepatitis	22
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials	22
Advances with glucocorticoids in the treatment of asthma: state of the art	22
The pharmacological management of chronic lower back pain	22
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma	20
Pharmacotherapeutic strategies for castrate-resistant prostate cancer	20
State-of-the-art treatment strategies for nontuberculous mycobacteria infections	20
Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)	19
Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases	19
An evaluation of avatrombopag for the treatment of thrombocytopenia	19
Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options	18

Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders	18
An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease	18
Cyclin-dependent kinase inhibitors for the treatment of lung cancer	18
Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art	18
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile	18
Current and new pharmacotherapeutic approaches for glaucoma	18
Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance	17
AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation	17
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies	17
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia	17
How urgent is the need for new antifungals?	17
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – too much for one drug?	17
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options	16
Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects	16
State-of-the-art pharmacotherapy for diabetic neuropathy	16
The pharmacological management of vertigo in Meniere disease	16
Careful use to minimize adverse events of oral antidiabetic medications in the elderly	16
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis	15
Selecting a pharmacotherapy regimen for patients with chronic insomnia	15
Ponesimod for the treatment of relapsing multiple sclerosis	15
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia	15
The role of amikacin in the treatment of nontuberculous mycobacterial disease	15
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout	15
An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage	15
Pharmacotherapeutic Options for Chronic Refractory Cough	15
The evolving atopic dermatitis management landscape	15
Novel synthetic treatment options for migraine	14
Quizartinib for the treatment of acute myeloid leukemia	14
Managing dyslipidemia in patients with Type 2 diabetes	14
The role of sulfonylureas in the treatment of type 2 diabetes	14
An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension	14
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.	14
A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain	13
An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective	13
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain	13
State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma	13
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia	13
Duvelisib for the treatment of chronic lymphocytic leukemia	13
Evaluating rimegepant for the treatment of migraine	13
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients	13
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease	13
Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems	13
Are thiazolidinediones a preferred drug treatment for type 2 diabetes?	13
Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer	12
The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)	12
Current and promising pharmacotherapeutic options for candidiasis	12
A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020	12
Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review	12
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG	12
Pharmacological management of secondary spinal cord injury	12

Cenobamate for the treatment of focal epilepsies	12
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	12
State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration	12
Management of cardiovascular disease in patients with systemic lupus erythematosus	12
The role of pharmacotherapy in the treatment of endometriosis across the lifespan	12
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis	11
Are drug treatment strategies really effective against alopecia areata?	11
Pharmacological strategies to treat attacks of episodic migraine in adults	11
Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia	11
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	11
Current and emerging pharmacotherapy for recurrent bacterial vaginosis	11
An update on the pharmacological management of pain in patients with multiple sclerosis	11
Drug treatment strategies for osteoporosis in stroke patients	11
An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis	11
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy	11
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics	11
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients	11
New perspectives on the definition, diagnosis, and treatment of true arterial hypertension	10
Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients	10
Advances in pharmacotherapy for diabetic foot osteomyelitis	10
Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma	10
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review	10
Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancer	10
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation	10
Evaluating vibegron for the treatment of overactive bladder	10
Advances with androgen deprivation therapy for prostate cancer	10
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma	10
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease	10
Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes	9
Current and emerging drug treatment strategies for peripheral arterial disease	9
Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature	9
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?	9
An update on the available and emerging pharmacotherapy for adults with testosterone deficiency available in the USA	9
An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain	9
Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment	9
Drug treatment options for acute promyelocytic leukemia	9
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma	9
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	9
Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics	9
Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability	9
Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?	9
Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis	9
Current and emerging systemic treatments targeting the neural system for chronic pruritus	9
The management of hematologic malignancies during the COVID-19 pandemic	9
Ensitrelvir as a potential treatment for COVID-19	9
Pharmacological management of human respiratory syncytial virus infection	9
Current pharmacotherapy for tic disorders	9
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?	9
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)	9
Evaluating pitolisant as a narcolepsy treatment option	9
Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist	8
Advances in the psychopharmacotherapy of bipolar disorder type I	8
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy	8
Advances in the pharmacological management of bacterial peritonitis	8
The clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine	8
Current and emerging drug treatment strategies for polycystic ovary syndrome	8
Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication	8
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations	8
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy	8
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer	8
Pharmacological treatment of focal epilepsy in adults: an evidence based approach	8
Protein kinase inhibitors for the treatment of prostate cancer	8
Current and future pharmacotherapy options for drug-resistant epilepsy	8
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer	8
Does hydroxychloroquine still have any role in the COVID-19 pandemic?	8
Pharmacological strategies for improving the prognosis of glioblastoma	8
State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma	8
Bexagliflozin for type 2 diabetes: an overview of the data	8
Advances in pharmacotherapies for hyperuricemia	8
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China	8
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	8
Evaluating ivosidenib for the treatment of acute myeloid leukemia	8
Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: an UK national cross-sectional audit	7
Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes	7
Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer	7
A review of the pharmacotherapeutic considerations for managing epilepsy in people with autism	7
Evaluating entrectinib as a treatment option for non-small cell lung cancer	7
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia	7
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer	7
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	7

Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer	7
Relapse prevention in panic disorder with pharmacotherapy: where are we now?	7
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	7
Pharmacotherapeutic considerations in women with multiple sclerosis	7
An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease	7
An evaluation of apalutamide for the treatment of prostate cancer	7
Advances in the pharmacological management of non-24-h sleep-wake disorder	7
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors	7
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis	7
An update on the impact of depression on the treatment of psoriasis	7
An update on antidepressant pharmacotherapy in late-life depression	7
Pharmacotherapy in Mast Cell Leukemia	7
Pharmacotherapeutic management of trigeminal neuropathic pain: an update	7
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	7
How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections?	7
Oral pharmacotherapeutics for the management of peripheral neuropathic pain conditions – a review of clinical trials	7
Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?	7
Pharmacological management of behavioral disturbances in patients with Alzheimer’s disease	7
The pharmacological treatment and management of hyperhidrosis	7
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion	7
What are the treatment options for resistant Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria?	7
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease	7
Combinational therapies for the treatment of advanced cervical cancer	7
Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma	6
Advances in pharmacotherapy for acute and recurrent pericarditis	6
Relugolix for the treatment of uterine fibroids	6
An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development	6
Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity	6
An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer	6
How treatable is narcolepsy with current pharmacotherapy and what does the future hold?	6
Balancing treatments for patients with systemic hypertension and glaucoma	6
Pharmacotherapeutic advances for recurrent urinary tract infections in women	6
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors	6
Current and future pharmacological agents for the treatment of back pain	6
Expert guidance on the management and challenges of long-COVID syndrome: a systematic review	6
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	6
Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion	6
An update on pharmacotherapeutic strategies for obesity	6
The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma	6
What place do carbamazepine-related antiepileptic drugs have in the modern day treatment of epilepsy?	6
Pharmacotherapeutic considerations for late-onset epilepsy	6
The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation	6
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV	6
Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer	6
Osilodrostat for the treatment of Cushing’s disease	6
Current and emerging pharmacotherapy for pediatric allergic rhinitis	6
What are the considerations for anti-hypertensive treatment in patients with Parkinson’s disease?	6
What is the impact of pharmacotherapy on psychotherapy for obsessive-compulsive disorder?	6
The complement system: a novel therapeutic target for age-related macular degeneration	6
Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations	6
Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes	6
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges	6
An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections	6
Current challenges in the pharmacological management of genitourinary syndrome of menopause	6
Advances in pharmacotherapy for neuroblastoma	6
Alitretinoin for the treatment of severe chronic eczema of the hands	6
Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19	6
Desvenlafaxine in the treatment of major depression: an updated overview	6
Pharmacological management of adult patients with acute respiratory distress syndrome	6
An evaluation of cabotegravir for HIV treatment and prevention	6
What’s new on the front-line of gout pharmacotherapy?	5
New and emerging pharmacological treatment options for acromegaly	5
The treatment of advanced lung adenocarcinoma with activating EGFR mutations	5
An update on current pharmacotherapy for vulvar cancer	5
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy	5
Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?	5
Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity	5
Rethinking the use of hypnotics for treatment of insomnia in the elderly	5
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	5
How do we address treating the negative symptoms of schizophrenia pharmacologically?	5
Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update	5
Evaluating upadacitinib for the treatment of psoriatic arthritis	5
Is pharmacotherapy useful for treating personality disorders?	5
What is the selection process for osteoarthritis pharmacotherapy?	5
Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	5
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update	5
Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease	5
Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far	5
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma	5
Azole resistance in Aspergillus species: promising therapeutic options	5
Tafenoquine for the treatment of Plasmodium vivax malaria	5
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date	5
Treatment strategies for isolated systolic hypertension in elderly patients	5
Advances in pharmacotherapy for head and neck cancer	5
Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime	5
The potential role of elagolix for treating uterine bleeding associated to uterine myomas	5
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care	5
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women	5
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)	5
Treating pulmonary hypertension in the elderly	5
Vibegron for the treatment of overactive bladder: a comprehensive update	5
Guidance for the pharmacological management of COVID-19 in the emergency setting	5
Drug treatment strategies for secondary diabetes in patients with acromegaly	5
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus	5
Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction	5